Sun Pharmaceutical Industries financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹15,300cr+10.5% on Q1 FY26
Net profit
₹2,901cr+26.5% on Q1 FY26
EBITDA margin
28.9%−2.2 pts on Q1 FY26
EPS
₹12.10+27.4% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue15,30013,851+10.5%
EBITDA4,4184,302+2.7%
EBITDA margin28.9%31.1%−2.2 pts
Profit before tax4,0993,173+29.2%
Net profit2,9012,293+26.5%
EPS₹12.10₹9.50+27.4%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹15,300 crNet profit₹2,901 crNet margin19.0%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
4,21,677————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
30,70430,70423,92517,87013,996
3103102683,4393,320
4,0824,0821,8702,8466,198
3,95,364————
59,91158,46252,57848,49743,886
—+11.2%+8.4%+10.5%—
17,84717,73115,27213,02311,647
29.8%30.3%29.1%26.9%26.5%
14,87114,79412,69610,4669,117
12,11711,50910,9659,6108,513
20.2%19.7%20.9%19.8%19.4%
₹50.41₹47.84₹45.55₹39.91₹35.32
—+5.0%+14.1%+13.0%—
—12,41914,07212,1354,959
—−3,609−2,129−2,202−2,086
8,8108,81011,9449,9332,874
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUNPHARMA₹1,757.50

Sun Pharmaceutical Industries Ltd.

· Pharma & Health
₹ CrorePeersCIPLADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹4.22L Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————4,21,677.0
- Cash, Equiv & ST Investments13,996.317,870.223,924.930,704.030,704.0
+ Minority Interest3,320.13,439.2267.9309.7309.7
+ Total Debt6,197.92,845.71,869.64,081.64,081.6
Enterprise Value————3,95,364.3
Revenue43,885.748,496.952,578.458,462.059,910.5
Growth %, YoY—+10.5+8.4+11.2—
EBITDA11,646.813,023.115,271.717,731.417,847.4
Margin %26.5426.8529.0530.3329.79
EBIT9,117.410,466.512,696.314,793.614,871.4
Net Income8,512.99,610.010,964.811,508.712,117.0
Margin %19.4019.8220.8519.6920.23
EPS, Adj (current shares)35.3239.9145.5547.8450.41
Growth %, YoY—+13.0+14.1+5.0—
Cash from Operations4,959.312,135.014,072.112,419.2—
Capital Expenditures-2,085.6-2,201.8-2,128.6-3,609.4—
Free Cash Flow2,873.89,933.211,943.58,809.88,809.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 199%.

Sun Pharma financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Sun Pharmaceutical Industries (NSE: SUNPHARMA) had a market capitalisation of ₹4,22,517 crore at the 29 October 2026 close (₹1,761.00 a share), a PE ratio of 34.9 on the last four quarters' profit and a price-to-book ratio of 5.06. In FY26 its consolidated net profit attributable to shareholders was ₹11,479 crore on revenue of ₹58,462 crore; in Q1 FY27 (April–June 2026) it was ₹2,895 crore, up 27.0% year on year. Its debt-to-equity ratio was 0.05 on 31 March 2026. Promoters held 52.68% of the shares on 30 September 2026.

Share price used
₹1,761.00 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026
Share price and live chart
₹1,761.00 · 29 Oct close

Sun Pharma at a glance · consolidated

Market cap
₹4,22,517 Crat ₹1,761.00 · 29 Oct close
PE ratio (last 4 quarters)
34.936.8 on FY26 profit
Price to book (PB)
5.06book value ₹348.31 a share
ROE (FY26)
14.7%−1.3 pts vs FY25ROCE 18.5%
Debt to equity
0.05net cash ₹28,455 Cr
Promoter holding
52.68%−1.8 pts vs 30 Jun 202630 September 2026
Dividend yield
0.91%₹16 a share in 12 months
Net worth
₹83,570 Cr+15.7% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹8,810 Cr−26.2% vs FY25

Questions

What is the Sun Pharma PE ratio today?

Sun Pharma's PE ratio is 34.9 at the 29 October 2026 close (₹1,761.00 a share): a market capitalisation of ₹4,22,517 crore divided by consolidated net profit attributable to shareholders of ₹12,096 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit attributable to shareholders (₹11,479 crore) it is 36.8.

What is the Sun Pharma PB ratio (price to book value)?

Sun Pharma's price-to-book (PB) ratio is 5.06 at the 29 October 2026 close: a market capitalisation of ₹4,22,517 crore divided by shareholders' equity (book value) of ₹83,570 crore on 31 March 2026. That is a book value of ₹348.31 per share against a share price of ₹1,761.00.

What is the Sun Pharma net worth?

Sun Pharma's net worth — shareholders' equity in its consolidated balance sheet — was ₹83,570 crore on 31 March 2026, up 15.7% from ₹72,218 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹4,22,517 crore at the 29 October 2026 close.

What is the Sun Pharma market cap?

Sun Pharma's market capitalisation was ₹4,22,517 crore (₹4.23 lakh crore) at the 29 October 2026 close: 239.93 crore shares at ₹1,761.00 each.

Is Sun Pharma debt free?

No. Sun Pharma had borrowings of ₹4,082 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.05. Its cash and current investments were ₹32,537 crore, so it held net cash of ₹28,455 crore.

What is the Sun Pharma EPS?

Sun Pharma's basic earnings per share (EPS) were ₹47.80 in FY26, against ₹45.60 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹50.40.

What is the Sun Pharma debt to equity ratio?

Sun Pharma's debt-to-equity ratio was 0.05 on 31 March 2026: borrowings of ₹4,082 crore against total equity of ₹83,880 crore. A year earlier, on 31 March 2025, it was 0.03.

What is the Sun Pharma book value per share?

Sun Pharma's book value per share was ₹348.31 on 31 March 2026: shareholders' equity of ₹83,570 crore divided by the 239.93 crore shares in issue, up 15.2% from ₹302.32 a year earlier. The share price at the 29 October 2026 close was ₹1,761.00.

What is the Sun Pharma dividend in 2026 and its record date?

In 2026, Sun Pharma has declared two dividends totalling ₹16 a share: ₹11 (interim) with record date 5 February 2026 and ₹5 with record date 7 July 2026.

What is the Sun Pharma ROE and ROCE?

In FY26, Sun Pharma's return on equity (ROE) was 14.7% and its return on capital employed (ROCE) was 18.5%. ROE is net profit attributable to shareholders divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 16.1% and ROCE 17.8%.

What is the Sun Pharma shareholding pattern?

On 30 September 2026, Sun Pharma's shares were held by promoters 52.68%, foreign portfolio investors (FII/FPI) 14.36%, domestic institutions (DII) 22.27% (including mutual funds at 13.01%) and retail and other non-institutional investors 10.70%. Over the year, FII holding was down 2.19 percentage points from 16.55% and DII holding was up 2.04 percentage points from 20.23%.

What are the Sun Pharma latest quarterly results?

Sun Pharma's latest results are for Q1 FY27 (April–June 2026), filed on 31 July 2026: consolidated net profit attributable to shareholders ₹2,895 crore, up 27.0% from ₹2,279 crore in Q1 FY26; revenue from operations ₹15,300 crore, up 10.5% year on year.

What is the Sun Pharma dividend yield?

Sun Pharma's dividend yield is 0.91% at the 29 October 2026 close: dividends of ₹16 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,761.00. They were ₹5 on 7 July 2026 and ₹11 on 5 February 2026 (interim).

What is the Sun Pharma promoter holding?

Promoters held 52.68% of Sun Pharma on 30 September 2026, down 1.80 percentage points from 54.48% the previous quarter and down 1.80 percentage points from 54.48% a year earlier, according to the shareholding pattern filed with NSE.

What is the Sun Pharma free cash flow?

In FY26, Sun Pharma generated ₹12,419 crore of cash from operations and spent ₹3,609 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹8,810 crore. In FY25 it was ₹11,944 crore.

What is the Sun Pharma revenue and profit in FY26?

In FY26 (April 2025–March 2026), Sun Pharma's consolidated net profit attributable to shareholders was ₹11,479 crore, up 5.0% from ₹10,929 crore in FY25, on revenue from operations of ₹58,462 crore (up 11.2%). Over three years, from FY23, net profit was up 35.5%.

How does the Sun Pharma PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit attributable to shareholders, Sun Pharma's PE ratio is 36.8, the highest of the four: Cipla 28.3, Dr Reddy's 26.8 and Lupin 17.1, a peer average of 24.0. Each is the company's market capitalisation at that price divided by its FY26 net profit.

Sun Pharma vs Cipla: how do they compare?

In FY26, Sun Pharma earned net profit attributable to shareholders of ₹11,479 crore on revenue of ₹58,462 crore, against ₹3,879 crore on ₹28,163 crore for Cipla. Sun Pharma's operating margin was 25.3% (Cipla 16.6%) and its return on equity 14.7% (Cipla 11.8%). At the 29 October 2026 close, Sun Pharma's market capitalisation was ₹4,22,517 crore against ₹1,09,706 crore for Cipla, and its PE ratio on FY26 profit 36.8 against 28.3.

When are the Sun Pharma next results?

Sun Pharma will announce its Q2 FY27 results (July–September 2026) on Friday, 30 October 2026, the date of the board meeting it has notified to the exchanges.

How does Sun Pharma compare with its peers?

On FY26 consolidated figures, against Cipla, Dr Reddy's and Lupin: Sun Pharma's operating margin of 25.3% is the second highest of the four (Cipla 16.6%, Dr Reddy's 13.0%, Lupin 26.6%; peer average 18.7%); its return on equity of 14.7% is the second highest of the four (Cipla 11.8%, Dr Reddy's 11.8%, Lupin 26.9%; peer average 16.8%); its revenue growth over three years of 10.0% a year is the third highest of the four (Cipla 7.4% a year, Dr Reddy's 11.0% a year, Lupin 18.9% a year; peer average 12.4% a year).

Where do these Sun Pharma figures come from?

From Sun Pharmaceutical Industries' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.